It is very uncertain whether ampicillin plus gentamicin changes all‐cause mortality maximum compared with penicillin plus gentamicin (very low certainty).
It is very uncertain whether piperacillin changes all‐cause mortality maximum compared with ampicillin plus amikacin (very low certainty).
It is very uncertain whether piperacillin changes serious adverse events maximum compared with ampicillin plus amikacin (very low certainty).
It is very uncertain whether piperacillin changes nephrotoxicity maximum compared with ampicillin plus amikacin (very low certainty).
It is very uncertain whether ampicillin plus gentamicin changes serious adverse events maximum compared with penicillin plus gentamicin (very low certainty).
It is very uncertain whether ampicillin plus gentamicin changes circulatory support maximum compared with penicillin plus gentamicin (very low certainty).
It is very uncertain whether ampicillin plus gentamicin changes neurological developmental impairment maximum compared with penicillin plus gentamicin (very low certainty).
It is very uncertain whether ampicillin plus gentamicin changes necrotising enterocolitis maximum compared with penicillin plus gentamicin (very low certainty).
It is very uncertain whether piperacillin plus tazobactam changes all‐cause mortality maximum compared with amikacin (very low certainty).
It is very uncertain whether piperacillin plus tazobactam changes serious adverse events maximum compared with amikacin (very low certainty).
It is very uncertain whether ticarcillin plus clavulanic acid changes all‐cause mortality maximum compared with piperacillin plus gentamicin (very low certainty).
It is very uncertain whether ticarcillin plus clavulanic acid changes serious adverse events maximum compared with piperacillin plus gentamicin (very low certainty).
It is very uncertain whether cefepime changes all‐cause mortality Maximum compared with ceftazidime (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether cefepime changes serious adverse events Maximum compared with ceftazidime (very low certainty).
It is very uncertain whether cefepime changes treatment failure Maximum compared with ceftazidime (very low certainty).